about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
23.74
0.92
(4.03%)
1.6M
XNAS Volume
XNAS 14 Nov, 2025 4:30 PM (EST)
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..